What Cellbri does

CellBri (CellBri Bio Innovation Technology LTD) is a Chinese-headquartered manufacturer of automated cell and gene therapy (CGT) manufacturing instruments, founded in 2020 and operating from Shenzhen with a global footprint spanning APAC, Europe, and North America. The company sells a dual-platform portfolio: the CellFAB One Series, an all-in-one enclosed system integrating sample preparation through final fill/formulation for clinical and commercial scale, and the Gentle Series, a suite of modular standalone units (Gentle Flex Pro for cell processing, Gentle n-MagS for nano-magnetic bead sorting, Gentle EXP for rocking-bioreactor expansion, Gentle P-Pac for fill and finish). Platforms are closed-system, 21 CFR Part 11 compliant, reagent-agnostic, and validated for Class C cleanroom operation; the company holds 260+ technical patents, ISO 13485 certification, FDA registration with DMFs on file, CE Marking, and EU MDR approval.

The company's commercial model is built on direct enterprise sales of capital equipment paired with recurring single-use consumables (cell bags, tubing sets, sterile samplers) and technical support services. It targets two primary customer segments: cell therapy developers and biotech companies running autologous and allogeneic programs (CAR-T, TCR-T, TIL, NK, MSC, iPSC), and CDMOs that need flexible automation to serve multiple client protocols. Distribution is supported by regional warehouses in Kansas City, MO and Budapest, Hungary enabling 3-5 business day shipping to North American and European customers. Named commercial deployment includes Grit Biotechnology's GT307 TIL program, which received FDA IND approval in February 2026 using CellBri's Gentle Flex-Pro and P-Pac systems.

CellBri monetizes via quote-based, multi-year enterprise contracts with undisclosed pricing. The company has scaled to 101-250 employees across 7 manufacturing centers with annual capacity of 5,000 instruments and 500,000 tubing sets, has secured 34+ GMP contract wins, and reports usage in 100+ pipeline products in China. It raised approximately $27.6M in mid-2024 led by 3E Bioventures and completed a subsequent financing in March 2025 with Changjin Holdings Industrial Capital and Fosun Health Capital. The company has no disclosed revenue figure, and ownership is private with no parent company or institutional investor profile publicly identified.

Name

Cellbri

Legal name

CellBri Bio Innovation Technology LTD

Website

https://cellbri.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

CellBri is a Shenzhen-headquartered manufacturer of automated cell and gene therapy manufacturing instruments, selling modular and all-in-one closed-system platforms (CellFAB One, Gentle Series) plus single-use consumables to cell therapy developers, biotech companies, and CDMOs across APAC, Europe, and North America.

Ownership category

akta.pro rank

Product category

Cell Therapy Manufacturing Automation Equipment

NAICS

Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

akta.pro secondary industry

Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH)

Keywords

• Cell therapy automation
• Automated cell processing
• Single-use consumables
• Bioreactor systems
• Fill and finish

Headquarters

HQ city

Shanzhen

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Automation Instruments and Platforms: Sale of automated cell processing systems including CellFAB One Series and Gentle Series modular instruments. Systems are sold directly to biotech companies and CDMOs with enterprise sales motion.
2. Single-Use Consumables: Single-use disposable kits, tubing sets, cell bags, samplers, and connectors. High-volume consumables business with 99% availability on critical components. Capacity to assemble half a million tubing sets per year.
3. Technical Support and Services: Technical guidance and customer support services for implementation and ongoing operations.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

CellBri designs, manufactures, and sells automated, closed-system cell therapy manufacturing instruments and single-use consumables for biotech companies and CDMOs. Its portfolio spans an all-in-one platform (CellFAB One Series) and modular units (Gentle Flex Pro, Gentle EXP, Gentle n-MagS, Gentle P-Pac) for processing CAR-T, TCR-T, TIL, NK, iPSC, and MSC therapies, complemented by consumables such as cell bags, tubing sets, samplers, and small tools (CB-Transfer, CB-LeakGuard). Revenue comes from direct sales of hardware and consumables together with technical support services.

Product overview

CellBri offers a dual-platform portfolio of automated cell therapy manufacturing systems: the CellFAB One Series (all-in-one integrated platform) and the Gentle Series (modular standalone systems). The CellFAB One platform provides end-to-end automation from sample preparation to final fill, configurable for different magnetic selection methods (nanobeads/microbeads) and incubation formats. The Gentle Series offers step-specific automation through individual modules including Gentle Flex Pro (cell processing), Gentle n-MagS (magnetic separation), Gentle EXP (bioreactor expansion), and Gentle P-Pac (fill/finish). Both platforms support CAR-T, TCR-T, NK, TIL, iPSC, and MSC therapies with reagent-agnostic, closed-system design, 21 CFR Part 11 compliance, and compatibility with GMP Class C cleanroom environments. The portfolio also includes companion consumables (CB-Transfer, CB-LeakGuard, cell bags, tubing sets, samplers) for complete workflow support.

Differentiator

Problem solved

Functional benefit

Brands

• CellFAB One: All-in-one automated cell processing system for clinical and commercial scale
• Gentle Series
• Gentle Flex Pro
• Gentle EXP
• Gentle n-MagS
• Gentle P-Pac
• CB-Transfer
• CB-LeakGuard

Products and services

• CellFAB One
• Gentle Flex Pro
• Gentle EXP
• Gentle n-MagS
• Gentle P-Pac
• CB-Transfer
• CB-LeakGuard
• Small Tools & Consumables

Quantifiable outcome

• 30% faster time to clinic
• +5 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Four partnerships are on record, tiered core and minor.

• BraccocoreStrategic or Co-development Partner · 4 February 2026Bracco Imaging partnered with CellBri to codevelop a flexible closed cell selection system using Bracco's lipid-based microbubble technology as a bead-free alternative to traditional magnetic bead approaches for cell enrichment and activation. This collaboration supports automated cell therapy manufacturing.
• LimulaminorStrategic or Co-development Partner · 4 February 2026Bracco partnered with Limula along with University of Fribourg researchers to develop an automated cell selection alternative using lipid-based microbubble technology.
• University of FribourgminorStrategic or Co-development Partner · 4 February 2026Academic research partnership with University of Fribourg researchers collaborating with Bracco and Limula on automated cell selection technology development.
• Grit BiotechnologycoreStrategic or Co-development Partner · 1 February 2026CellBri provides manufacturing technology support to Grit Biotechnology for their GT307 next-generation dual gene-knockout TIL therapy. CellBri's Gentle Flex-Pro (automated cell processing) and P-Pac (fill and finish) systems are used in the manufacturing workflow. GT307 received FDA IND approval in February 2026.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Ori Biotech: UK-based emerging player in automated cell and gene therapy manufacturing with the IRO platform. Competes directly with CellBri in closed-system cell therapy automation for both autologous and allogeneic workflows.
• ScaleReady: Joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf offering the G-Rex bioreactor platform for cell therapy manufacturing. Comparable focus on scalable cell expansion systems used in CGT workflows.
• PBS Biotech: US-based company offering single-use bioreactors for cell therapy and regenerative medicine manufacturing. Comparable in providing closed-system, GMP-compliant cell expansion platforms to cell therapy developers and CDMOs.
• Akadeum Life Sciences: Emerging player in cell separation technology using microbubble-based approaches, directly comparable to CellBri's Bracco partnership strategy. Competes in cell isolation and activation workflows within cell therapy manufacturing.

Direct peers

• Miltenyi Biotec: German-headquartered leader in cell processing instruments and reagents, including the Prodigy platform for automated cell therapy manufacturing. Closely comparable product offering (closed-system automation) and target customer base (biotech and CDMOs).
• Terumo BCT: Specializes in blood component and cell processing equipment with cell therapy automation offerings. Direct competitor to CellBri in cell processing instruments for CAR-T and other cell therapy manufacturing workflows.

Broad incumbents

• Lonza: Global CDMO leader with the Cocoon automated cell therapy manufacturing platform. Overlaps with CellBri in cell therapy automation hardware but operates primarily as a CDMO services provider, offering automation as part of broader manufacturing services.
• Cytiva: Danaher-owned life sciences tools provider with cell therapy automation solutions including the Sefia and Xuri cell expansion systems. Comparable in offering closed-system automation for cell therapy manufacturing to biotech and CDMO customers.
• Fresenius Kabi: Global healthcare company with cell therapy manufacturing solutions including the Lovo and Feb CAT-S cell processing systems. Comparable automation offering targeting similar biotech and CDMO customers in cell therapy.
• Beckman Coulter Life Sciences: Provides cell sorting, washing, and processing instruments including the MoFlo Astrios and other cell therapy workflow tools. Comparable in providing instrumentation for cell therapy manufacturing, though broader portfolio.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cellbri

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellbri